Hengrui Pharma(SH:600276) Sou Hu Cai Jing·2025-09-05 03:20Group 1 - The Hong Kong stock market is experiencing an upward trend, with the innovative pharmaceutical sector showing strong performance, as evidenced by a 3.5% increase in the Hang Seng Innovative Drug Index and over 400 million yuan in trading volume for the Hang Seng Innovative Drug ETF (159316) [1] - Hengrui Medicine announced a significant overseas business development (BD) deal worth over 1 billion USD for its drug HRS-1893, with an upfront payment of 65 million USD, aimed at expanding its market reach and providing quality treatment options globally [1] - Guosen Securities highlighted that the innovative drug sector has performed well in the first half of the year, driven by successful BD collaborations, excellent clinical data, and supportive policies, indicating a rapid increase in the commercial value of newly launched products [1] Group 2 - The Hang Seng Innovative Drug Index has been adjusted to exclude contract research organizations (CROs), achieving a "purity" of 100% for innovative drug companies, which allows for a more accurate reflection of the overall performance of China's innovative pharmaceutical sector [2] - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this newly adjusted index, providing investors with a precise opportunity to capitalize on the growth of the innovative drug industry [2]